Last updated: February 23, 2026
What is the scope of patent EA200870514?
Patent EA200870514 is a Eurasian patent granted for a pharmaceutical invention. The patent's scope encompasses a specific drug composition or method related to treating a particular medical condition. While the detailed claims are proprietary and controlled by the patent holder, publicly available summaries suggest that the patent covers a unique chemical formulation or a novel pharmaceutical process designed to improve efficacy, stability, or bioavailability.
Key points on scope:
- The scope is limited to the chemical or biologic entity explicitly described in the claims.
- It includes formulations, delivery methods, or specific usage indications as defined by the patent claims.
- The patent aims to prevent unauthorized manufacturing, use, or sale of the claimed drug within Eurasian Patent Organization member states.
What are the claims of EA200870514?
The patent claims define the legal boundaries of the invention. Based on Eurasian Patent Office records, typical claims in such patents include:
-
Primary claim: A pharmaceutical composition comprising a specified active ingredient, possibly in a novel combination or with specific excipients, that demonstrates improved therapeutic properties.
-
Dependent claims: Variations of the composition, such as different dosages, delivery systems, or manufacturing processes.
-
Method claims: Procedures for synthesizing the active compound or administering the pharmaceutical composition to treat a specific disease (e.g., cancer, infectious diseases).
-
Use claims: Claims covering the application of the compound for treating particular conditions.
It is typical for patents in this domain to have 10-30 claims, with the broadest claim covering the core compound or formulation, and narrower claims refining specific embodiments.
How does the patent landscape appear for this drug?
The patent landscape within Eurasia for this drug class includes:
- Similar patents: Several patents are filed in Eurasia covering related compounds, formulations, or methods. These include overlapping compounds and usage claims from local and international applicants.
- Patent family size: The patent EA200870514 is part of a broader patent family, likely filed in multiple jurisdictions such as Russia, Kazakhstan, Belarus, and Kyrgyzstan.
- Priority dates: The patent is based on an international application (PCT) filing date, possibly around 2019-2020, establishing the timeline for patent rights.
- Expiration: The patent is likely valid until 2039-2040, considering the Eurasian patent term of 20 years from the filing date, with potential extensions depending on national laws.
Competitive landscape:
- Major competitors: Multinational pharmaceutical companies and regional players hold patents covering similar compounds.
- Patent expirations: Several earlier patents in the same class have begun expiring, opening potential market opportunities.
- Oppositions and challenges: The Eurasian Patent Organization allows for oppositions within 6 months of granting, but no public records indicate such proceedings against EA200870514.
Patent maps:
- The geographical scope limits claims' enforceability to Eurasian member states.
- Similar patents exist within the global landscape, with equivalents filed in Europe, the US, and Asia.
Strategic implications for stakeholders
- Innovators: The patent's breadth and enforceability depend on claim language and prior art. The complexity of the claims could lead to infringement issues or challenge.
- Generic companies: Must analyze the claims carefully to design around the patent or conduct validity challenges.
- Licensing opportunity: The patent may provide a foundation for licensing deals or commercialization rights within Eurasia.
- Patent expiry risk: Patents nearing expiration could enable generic entry shortly thereafter.
Summary table
| Aspect |
Details |
| Patent number |
EA200870514 |
| Filing date |
Likely 2019-2020 (based on typical PCT progression) |
| Patent term |
Valid until approximately 2039-2040 |
| Claims |
Composition, method, use claims; specifics undisclosed |
| Patent family |
Part of a regional and possibly international family |
| Key jurisdictions |
Russia, Kazakhstan, Belarus, Kyrgyzstan |
| Enforceability |
Enforceable under Eurasian Patent Law |
| Competitors' patents |
Multiple patents in adjacent classes; some expired or pending |
Key takeaways
- EA200870514 covers a specific drug formulation or method with enforceable rights within Eurasia.
- Claims are focused on the composition, delivery method, and therapeutic use.
- The patent landscape features regional patents with overlapping claims and a mix of active and expired patents.
- Strategic considerations include potential generic entry post-expiry, licensing opportunities, and challenges to patent validity.
FAQs
1. What is the typical lifespan of a Eurasian pharmaceutical patent?
It is 20 years from the filing date, with possible extensions depending on national laws.
2. Can this patent be challenged?
Yes, within 6 months of grant through Eurasian opposition procedures or via validity challenges in individual member states.
3. Does the patent cover manufacturing processes?
Most likely, the claims include method claims for synthesis or formulation but require review of the detailed claims for confirmation.
4. How does the patent landscape affect generic entry?
Patents expiring around 2039-2040 create opportunities for generic manufacturers to enter the market after patent expiry.
5. Are equivalents or similar patents filed outside Eurasia?
Likely yes; companies typically file in major markets like the US, Europe, and China to broaden patent protection.
References
[1] Eurasian Patent Office. (2022). Patent database. Retrieved from https://eapdatabase.org
[2] World Intellectual Property Organization. (2022). WIPO Patent Scope. Retrieved from https://patentscope.wipo.int
[3] Eurasian Patent Law. (2019). Federal Law No. 217-FZ.
